Ignite Creation Date:
2024-05-06 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 2:27 PM
Study NCT ID:
NCT05286437
Status:
RECRUITING
Last Update Posted:
2024-03-05
First Post:
2022-03-09
Brief Title:
Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole
Sponsor:
National Cancer Centre Singapore
Organization:
National Cancer Centre Singapore
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Advanced Breast Cancer | View |